The presence of autoantibodies to multiple islet autoantigens confers high risk for development of Type 1 diabetes. Four major autoantigens are established (insulin, glutamate decarboxylase, IA-2, and zinc transporter-8), but the molecular identity of a fifth, a 38kDa membrane glycoprotein (Glima), is unknown. Glima antibodies have been detectable only by immunoprecipitation from extracts of radiolabeled islet or neuronal cells. We sought to identify Glima to enable efficient assay of these autoantibodies. Mouse brain and lung were shown to express Glima. Membrane glycoproteins from extracts of these organs were enriched by detergent phase separation, lectin affinity chromatography and SDS-PAGE. Proteins were also immunoaffinity purified from brain extracts using autoantibodies from diabetic patients' sera before SDS-PAGE. Eluates from gel regions equivalent to 38kDa were analyzed by LC-MS/MS for protein identification. Three proteins were detected in samples from the brain and lung extracts, and in the immunoaffinity purified sample, but not the negative control. Only tetraspanin-7, a multipass transmembrane glycoprotein with neuroendocrine expression, had physical characteristics expected of Glima. Tetraspanin-7 was confirmed as an autoantigen by demonstrating binding to autoantibodies in Type 1 diabetes. We identify tetraspanin-7 as a target of autoimmunity in diabetes, allowing its exploitation for diabetes prediction and immunotherapy.
INTRODUCTION
Detection of circulating autoantibodies to pancreatic islets (1) , and identification of their molecular targets (2) , has allowed development of high throughput autoantibody assays for clinical diagnosis of Type 1 diabetes and identification of individuals at risk for disease. Evidence from both animal studies and human trials indicate that Type 1 diabetes may be prevented in individuals at risk (3; 4) . Hence, a range of therapies to interfere with immune responses has proved effective in preventing disease development in animal models of diabetes (5) and in slowing the loss of beta cell function occurring in the months following disease diagnosis in man (6) (7) (8) . There is now a focus on development of procedures to interfere specifically in immune responses that cause Type 1 diabetes, requiring knowledge of the major targets of the autoimmune response. There is no single common autoimmune target and individuals differ in antigen specificity of autoimmune responses they develop. Four major humoral autoantigens have been identified in Type 1 diabetes by defining the specificity of autoantibodies in the disease: insulin (9), glutamate decarboxylase (10), IA-2 (11), and zinc transporter-8 (ZnT8) (12). Autoantibodies to a fifth, a 38kDa glycosylated membrane protein (Glima), have been detected in 19-38% of Type 1 diabetic patients, with significantly higher prevalence (up to 50%) in children (13) (14) (15) . The molecular identity of Glima has for many years proved elusive, hampering the characterization of autoimmunity to the protein and the development of sensitive, specific autoantibody assays. Glima is expressed in pancreatic beta and neuronal cell lines, is hydrophobic, heavily N-glycosylated, having affinity for the lectin wheat germ agglutinin, and has a core protein backbone of approximately 22kDa (13) (14) (15) . The aim of
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RESEARCH DESIGN AND METHODS
Patients. Serum samples were obtained from 40 Type 1 diabetic patients (12-6 y) within 6 months of diagnosis from clinics in West Yorkshire with informed consent for screening for high-titer Glima antibodies, 94 additional patients (12-63 y) for assay verification and 52 non-diabetic individuals as negative controls. Approval for analysis of autoantibodies in sera from these individuals was obtained from the Yorkshire and the Humber -Bradford Leeds Research Ethics Committee.
Screen of type 1 diabetic patient sera for Glima antibodies. Glima antibodies were
detected by a modification of immunoprecipitation assays previously described (13) (14) (15) using the neuronal mouse cell line GT1.7 as source of antigen. Endogenous proteins in GT1.7 cells were labeled by incubation in methionine-free DMEM medium containing 4 MBq/ml 35 S-methionine for 7 h at 37°C. Cells were washed with Hepes buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 10 mM benzamidine) and stored at -80°C. Frozen cell pellets were extracted in Hepes buffer containing 2% Triton X-100 for 2 h on ice and insoluble material removed by centrifugation at 15,000 g for 15 min at 4°C. Membrane glycoproteins were isolated by incubating cell extracts with wheat germ agglutininagarose on ice for 30 min and, after washing in Hepes buffer containing 0.5 mM methionine, 100 mg/l bovine serum albumin and 0.5% Triton X-100, eluted in the same buffer containing 0. Partial purification of Glima from mouse brain and lung. Mouse brain and lung,
shown to express Glima in the tissue screen (see Results), were homogenized in ice-cold homogenization buffer in a Dounce homogenizer and cell debris removed by centrifugation at 500 g for 5 min at 4°C. A membrane fraction was prepared by centrifugation of the supernatant at 10,000 g for 15 min at 4°C, and the pellet washed and extracted in 2% Triton X-114 extraction buffer for 2 h at 4°C. Insoluble material was removed by centrifugation at 10,000 g for 15 min at 4°C and a detergent phase prepared by heat-induced phase-separation as previously described (13). Fractions were added to wheat germ agglutinin-agarose at a ratio of 100 µl lectin-agarose to 5 mg total protein and incubated overnight at 4°C with gentle mixing. The beads were washed twice with Hepes buffer containing 0.5% Triton X-100 and twice in NOG buffer (1% n-octyl- Triton X-114 detergent phase-purified amphiphilic proteins from mouse brains prepared as above were added to the Glima antibody-positive and -negative beads and incubated overnight at 4°C with mixing. Beads were washed with 0.5% Triton X-100 in Hepes buffer prior to elution in 2% SDS at 90°C for 10 min. The eluate was concentrated to 20 µl using the SDS-PAGE Sample Preparation Kit, subjected to SDS-PAGE and Colloidal
Coomassie gel staining as above, and gel slices in the 38,000 M r region excised for mass spectrometry. MS/MS analyses were conducted using collision energy profiles that were chosen based on the mass-to-charge ratio (m/z) and the charge state of the peptide.
In
Tandem mass spectra were processed into peak lists using Proteome Discoverer (version Immunohistochemistry. Tspan7 localization in rodent tissues was performed by immunohistochemistry. Sections of formalin-fixed paraffin-embedded rat brain, pituitary, pancreas, adrenal gland, lung, muscle, heart, liver, kidney, spleen, and thymus were dewaxed and subjected to epitope retrieval in a microwave pressure cooker in 10 mM citric acid pH 6.0, 0.05% Tween 20. Endogenous peroxidase activity was inhibited with 0.3% H 2 O 2 and non-specific binding blocked with 25% non-immune swine serum in PBS.
Primary antibody to Tspan7 (Anti-TM4SF2, Sigma-Aldrich; HPA003140) was applied at 1:1,000 dilution and incubated overnight at 4°C. Antibody labeling was detected with the Envision kit (Dako, Ely, UK) according to the manufacturer's instructions, sections counterstained in Meyers Haematoxylin (Sigma-Aldrich) and visualized by microscopy. Lysozyme (1 mg/ml) in PBS containing 10 mM benzamidine, 1 mM PMSF for 30 min at room temperature, followed by incubation in Triton X-100 (0.1%) for 5 min and DNase
(1 µg/ml) for 10 min. The lysate was centrifuged at 10,000 × g for 10 min at 4°C, and the supernatant used in immunoprecipitation assays.
Tspan7 binding to autoantibodies in Type 1 diabetes. Individual Glima antibodypositive and -negative human sera (15 µl) were incubated with protein A-Sepharose (15 µl), and the immunoglobulin captured was cross-linked to beads with dimethyl pimelimidate (18) . Bead-bound antibodies were incubated overnight at 4°C with Triton X-100 extracts of mouse brain, or with lysates of E. coli expressing recombinant mouse Tspan7. Beads were washed three times in 0.5% Triton X-100 in Hepes buffer and captured proteins subjected to SDS-PAGE and Western blotting using rabbit anti-Tspan7
antibody (anti-TM4SF; Sigma-Aldrich HPA003140) at 1:250 dilution overnight at 4°C.
Immunoprecipitated Tspan7 was detected with goat anti-rabbit IgG-peroxidase (product A0545; Sigma-Aldrich;) and SuperSignal West Pico Chemiluminescent substrate (Thermo Fisher Scientific).
Luminescent immunoprecipitation assay for detection of Tspan7 antibodies
The coding region of human Tspan7 was cloned into the pCMVTnT vector as a fusion with Nanoluciferase (Promega, Southampton, UK) at the 3' end. The construct was Triton-X-114 extracts were subjected to phase separation as described above and 
RESULTS
Selection of Glima antibody-positive sera. To identify patients with high levels of Glima antibodies for immunoaffinity purification, sera from 40 recent-onset Type 1 diabetic patients were screened by immunoprecipitation using radiolabelled mouse GT1.7
cell extracts (Fig 1) . Intense diffuse 38,000 M r bands typical of Glima were detected for three patients, indicative of high levels of Glima antibodies (029, 037 and 110 in Fig. 1 ).
These three sera were used for subsequent Glima characterization and purification.
Weaker 38,000 M r bands indicative of Glima antibody positivity were detected in an additional 11 patients (Fig 1) .
Tissue specificity of Glima expression. To identify large organs in which Glima is expressed at suitably high levels for antigen purification, competitive binding studies were performed in which detergent extracts of normal mouse tissues acted as unlabeled competitors with radiolabeled Glima from GT1.7 cell lysates for binding to antibodies in serum from the strong Glima antibody-positive patient, 029. Extracts of brain, pituitary, and lung reduced the intensity of radiolabeled 38,000 M r protein, indicative of Glima immunoreactivity in these tissues (Fig. 2) .
Identification of Glima candidate proteins by mass spectrometry. Extracts enriched for glycosylated membrane proteins from both brain and lung were prepared using Triton X-114 phase separation of amphiphilic membrane proteins followed by wheat germ agglutinin affinity purification. Proteins migrating at 38,000 M r by SDS-PAGE were trypsinized and analyzed by LC-MS/MS. A total of 65 candidates in brain and 25 in lung were identified, of which 20 were common to both samples, (Supplementary Table 1 ).
Glycosylated membrane proteins immunoprecipitated from brain extracts by antibodies in the high Glima antibody titer patients' serum pool were also subjected to SDS-PAGE and LC-MS/MS analysis and three of the 20 protein candidates common to brain and lung were present in the Glima antibody-positive sample, but not the negative control (Supplementary Table 1 ). These were: 1) cytoplasmic actin-1 (Actb), a ubiquitous nonglycosylated cytoskeletal protein with a predicted molecular weight of 42 kDa; 2) guanine nucleotide-binding protein G(i) subunit alpha-2 (Gnai2), a non-glycosylated membrane associated 40 kDa protein with a wide tissue distribution; and 3) tetraspanin-7
(Tspan7), a hydrophobic four-transmembrane domain protein with core molecular weight 27.5 kDa, five putative N-glycosylation sites and a neuroendocrine distribution. Tspan7
closely matched the known properties of Glima and additional studies were performed to compare properties and validate Tspan7 as the autoantigen.
Localization of Tspan7 in rat tissues. The tissue distribution of Tspan7 was determined
by immunohistochemistry for comparison with patterns of Glima expression in competition experiments above. Strong immunolabeling for Tspan7 was detected in the rat brain, in particular the cerebral cortex, hippocampus, cerebellum, striatum and thalamus (Fig. 3A) , in the pancreatic islets (Fig. 3B) , in the anterior pituitary (Fig. 3C) , and in epithelial cells lining the alveoli in the lung (Fig. 3D ). These observations agree with the Glima immunoreactivity described above, and previously (13, 15). Weak Tspan7 immunolabelling was also found in cells of the adrenal gland (Fig. 3E) . No evidence of Tspan7 expression was found in the exocrine pancreas (Fig. 3B) , muscle, heart, liver, kidney, spleen, or thymus (not shown).
Immunoprecipitation of Tspan7 by antibodies in Type 1 diabetes. To demonstrate
that Tspan7 is a target for autoantibodies in Type 1 diabetes, extracts of mouse brain and lysates of E. coli expressing recombinant mouse Tspan7 were subject to immunoprecipitation with Glima antibody-positive and -negative sera followed by
Western blotting with a rabbit antibody to Tspan7. A 38,000 M r band representing Tspan7 was selectively immunoprecipitated from mouse brain detergent extract by three Glima antibody-positive sera, but not by control samples. The bands detected comigrated with the brain lysate control (Fig. 4A ). Antibodies in Type 1 diabetic patients' sera also specifically immunoprecipitated Tspan7 from bacterial lysates containing recombinant protein (Fig 4B) . Here, the protein migrated at approximately 22,000 M r , consistent with a lack of glycosylation in bacteria (Fig. 4B) . The results confirm Tspan7 as a target of autoantibodies in Type 1 diabetes.
Analysis of Tspan7 antibodies by luminescence immunoprecipitation assay
Patients screened for Glima antibodies were analyzed for Tspan antibodies by immunoprecipitation of recombinant Nanoluciferase-tagged human Tspan7. Western blotting with rabbit polyclonal antibodies to both Nanolucoferase and Tspan7 detected diffuse 38,000 M r bands (the expected size of the non-glycosylated fusion protein) as the dominant immunoreactivity in cells transfected with the construct, with additional bands at approximately 80,000 M r (Fig 4C) . The 38,000 Mr protein partitioned into the detergent on temperature-induced phase separation in Triton X-114. Transfected cell extracts were used in immunoprecipitation studies with normal control sera or with sera from Glima antibody-positive and -negative Type 1 diabetic patients. All but one (V015) of the controls (n=52) had low Tspan7 antibodies (Fig 4D) . Four patients with high
Glima antibodies (Fig 1) also immunoprecipitated high luciferase activity in the Tspan7 antibody assay (Fig 4D) and significantly higher levels of Tspan7 antibodies were found in Glima antibody-positive patients than those Glima antibody negative (p<0.0001; Mann Whitney U test). In competition assays, natural or recombinant Tspan7 in brain or E coli extracts partially (control sample V015), or completely (Glima antibody positive Type 1 diabetic patients) blocked antibody binding to the Nanoluciferase-Tspan7 construct ( Fig   4E) . Control V015 did not bind Tspan7 from mouse brain extracts when tested in the Western blotting assay. A second set of 94 recent onset Type 1 diabetic patients were also tested in the Tspan7 antibody assay. Using a cut-off of mean + 3SD of controls (omitting the outlier), 40 (43%) were positive for Tspan7 antibodies (Fig 4D) .
DISCUSSION
Autoantibodies to "Glima" in Type 1 diabetes were first reported in 1996 (13), but its molecular identity has since then remained unknown. We used mass spectrometry of Glima-enriched fractions of brain and lung to search for likely candidates for Glima. LC-MS/MS analysis identified 65 proteins in 38,000 M r gel samples of amphiphilic membrane glycoproteins from brain and 25 from lung, of which 20 were common to both (Supplementary Table 1 
